{"id":34392,"date":"2019-04-29T12:08:13","date_gmt":"2019-04-29T11:08:13","guid":{"rendered":"https:\/\/clarivate.com\/?p=34392"},"modified":"2024-07-05T16:45:05","modified_gmt":"2024-07-05T16:45:05","slug":"oncology-landscape-stays-hot-for-dealmakers","status":"publish","type":"post","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/blog\/oncology-landscape-stays-hot-for-dealmakers\/","title":{"rendered":"Oncology landscape stays hot for dealmakers"},"content":{"rendered":"
\"\"

Jamie Munro<\/p><\/div>\n

<\/div>\n

Intense competition for dealmaking in oncology \u201cshows no sign of abating.\u201d That\u2019s the key takeaway from recent analysis developed by Jamie Munro and Helen Dowden, of Clarivate Analytics<\/i>. Their article, \u201cOncology dealmaking trends<\/a>,\u201d was featured in the Biopharma Dealmakers<\/i> supplement to Nature Biotechnology<\/i> and Nature Reviews: Drug Discovery<\/i>.<\/p>\n

Munro, global practice leader, portfolio and licensing, at Clarivate<\/i>, spoke recently about the robust outlook for the sector.<\/p>\n

 <\/p>\n

Q: You\u2019ve written analyses of the dealmaking landscape in oncology in back-to-back years. What has changed?<\/h6>\n

Munro:<\/b> Overall, oncology remains a hugely hot area. One of the things we noticed this year is that there has been a lot of activity and interest in earlier stage deals. It is difficult to know how much of that is down to a lack of supply of clinical stage deals, or that companies are more willing to take the risk and go earlier, or because they believe it\u2019s less risky to do so now.\u00a0<\/span><\/p>\n

Also, immuno-oncology, which was already a significant area a year ago, really is dominating deals relative to other parts of oncology.\u00a0<\/span><\/p>\n

 <\/p>\n

Q: The Bristol-Myers Squibb-Celgene deal \u2013 at $74 billion \u2013 got everyone\u2019s attention one week into the new year. What does the merger of those two players mean not just for oncology dealmaking<\/a> but for the industry as a whole?<\/h6>\n

Munro:<\/b> No one knows for sure, but it\u2019s going to be fascinating. Are we at the start of a new wave of big deal making or is this more of a one-off?\u00a0<\/span><\/p>\n

One of the players \u2013 Celgene, obviously \u2013 is big in the biotech space. What does it mean for the likes of companies like Gilead, the biotech players that people may be looking at it? Is this a bellwether? Does it create pressure on them?\u00a0 <\/span>I think the answer is likely to be: yes, it does.<\/p>\n

Meanwhile, the jury is still out on productivity. Volumes have been relatively good in the last few years, but there is still a big question over big pharma\u2019s ability to generate sustainable value and affordable medicines.\u00a0<\/span><\/p>\n

 <\/p>\n

Q: Your analysis in Nature<\/i> includes a focus on how Chinese companies have become active in-licensors of oncology assets. Will that continue?<\/h6>\n

Munro:<\/b> The uptick is significant when you look at the region. The total is still relatively small when compared to the U.S., but it\u2019s the pace of acceleration in China that catches your attention. And when you look at the companies behind the deals, the backers, they are big players in the region. So, it\u2019s hard to see how we won\u2019t see strong activity there going forward.\u00a0<\/span><\/p>\n

 <\/p>\n

Q: We liked the phrase \u201ctechnology drivers\u201d in your Nature <\/i>article. Which technologies do you anticipate will continue to drive dealmaking in oncology?<\/h6>\n

Munro:<\/b> It\u2019s obviously focused around immuno-oncology. We\u2019ve seen big activity around CAR-T. Some of the technology is still not there yet \u2013 for patients \u2013 but we are seeing huge progress in things like CRISPR and gene editing. Anything around those hot areas that we have already seen and around cell and gene therapies more generally are likely to lead to sustained interest and attract significant premiums.<\/p>\n

 <\/p>\n

Q: Will the space stay hot, perhaps warranting another follow-up in 2020?<\/h6>\n

Munro:<\/b> The ingredients are there for it to stay hot. Number one, we have the productivity challenge. Several companies are struggling to be successful and to deliver sustainable returns. It takes more than a decade in some cases to turn the big ship around, the R&D ship, from start to end, and most CEOs aren\u2019t in place for that long. But one of the areas where they can make an impact more quickly is through business development.<\/a> \u00a0<\/span><\/p>\n

Secondly, companies continue to struggle with other therapeutic areas \u2013 when we look at neuroscience and neurodegenerative diseases, for example \u2013 you can see that there will be even more interest in areas such as oncology that have proven to be more successful and less clinically demanding at least in some respects.<\/p>\n

Then let\u2019s not forget the regional aspect, as well. We talked about China. One of the things we noticed that\u2019s really pronounced with China is the area of focus: They are investing heavily in immuno-oncology \u2013 in oncology in general, but especially in immuno-oncology. They are placing their bets squarely in this area.\u00a0<\/span><\/p>\n

 <\/p>\n

Dive further into the oncology sector and hear best practices for partnering in the free webinar, \u201cOncology Investment & Partnering Trends,\u201d sponsored by Clarivate Analytics and the Biotechnology Innovation Organization (BIO) on May 9.\u00a0<\/span><\/em><\/p>\n

Sarah Hardison, Clarivate\u2019s therapeutic area director, and Willie Reaves, director, partnering, products & services at BIO, are the featured speakers.\u00a0<\/span><\/em><\/p>\n

Register here.<\/i><\/i><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Intense competition for dealmaking in oncology \u201cshows no sign of abating.\u201d That\u2019s the key takeaway from recent analysis developed by Jamie Munro and Helen Dowden, of Clarivate Analytics. Their article,…<\/p>\n","protected":false},"author":2,"featured_media":266591,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_links_to":"","_links_to_type":0,"footnotes":""},"categories":[19,21],"tags":[124,84,159],"class_list":["post-34392","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-life-sciences-healthcare","tag-healthcare-dealmaking","tag-oncology","tag-portfolio-strategy","clarivate-product-biopharma"],"acf":[],"lang":"en","translations":{"en":34392},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/34392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/comments?post=34392"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/34392\/revisions"}],"predecessor-version":[{"id":266417,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/34392\/revisions\/266417"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media\/266591"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=34392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/categories?post=34392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/tags?post=34392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}